08/22/2025 – 06:04 AM
AUSTIN, Texas — (BUSINESS WIRE) — Natera, Inc. (NASDAQ: NTRA), a major player in the cell-free DNA testing and precision medicine space, has announced the publication of over 300 peer-reviewed papers featuring its cutting-edge technology. This milestone underscores Natera’s sustained commitment to rigorous clinical validation and scientific advancement.
These publications, appearing in top-tier journals such as Nature, Nature Medicine, the American Journal of Transplantation, and the American Journal of Obstetrics and Gynecology, highlight significant breakthroughs in early disease detection and optimized clinical decision-making. The sheer volume and quality of these publications solidify Natera’s position as a leader in the field.
Key highlights from the publications include:
- Over 150 publications focused on Natera’s oncology portfolio, with more than 140 spotlighting the clinicalutility of Signatera™ across a spectrum of cancer types. This data continues to build the case for Signatera’s role in transforming cancer management.
- Over 100 publications showcasing Natera’s Women’s Health technologies, revealing comprehensive datasets on non-invasive prenatal testing, carrier screening, and other related applications. This demonstrates the breadth of Natera’s impact on reproductive health.
- More than 60 publications pertaining to its Organ Health solutions, with significant data supporting the use of Natera’s technology in heart, kidney, and lung transplantation. This reveals potential for improved outcomes in transplant medicine.
“Reaching 300 peer-reviewed publications isn’t just a number; it’s a powerful validation of our unwavering scientific investment and the tangible value our technology delivers to patients,” stated Minetta Liu, M.D., chief medical officer for oncology at Natera. “These data are a testament to our dedication to enhancing clinical care across diverse medical disciplines. We extend our gratitude to our research collaborators and the countless patients whose participation makes this crucial work possible.”
About Natera
Natera™ is a global pacesetter in cell-free DNA and genetic testing, with a strong focus on oncology, women’s health, and organ health. The company’s mission is to integrate personalized genetic testing and diagnostics into standard clinical practice to safeguard health and pave the way for earlier, more targeted interventions for longer, healthier lives. Natera’s tests, backed by more than 300 peer-reviewed publications demonstrating excellent performance, are processed in ISO 13485-certified and CAP-accredited laboratories under CLIA regulations in Austin, Texas, and San Carlos, California. For further information, visit www.natera.com.
Forward-Looking Statements
This press release contains forward-looking statements that are subject to risks and uncertainties. Natera cautions readers that actual results may differ materially from those anticipated in these statements. Factors that could cause such differences include, but are not limited to, the success of clinical and other studies, the reliability, accuracy, and performance of Natera’s tests, as well as the benefits of the company’s tests and product offerings. A detailed discussion of risks and uncertainties can be found in Natera’s filings with the SEC, including its recent Forms 10-K and 10-Q, available at www.natera.com/investors and www.sec.gov. Natera undertakes no obligation to update these forward-looking statements.
Source: Natera, Inc.
Original article, Author: Jam. If you wish to reprint this article, please indicate the source:https://aicnbc.com/7854.html
